Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Combined COVID-19 and Influenza mRNA Vaccines
NCT05596734Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BNT162b2 + BNT161 in coronavirus disease 2019 (COVID-19), influenza, sponsored by BioNTech SE. Started Oct 2022; status: completed.
02
Drugs
BNT162b2 + BNT161
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT05596734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05596734.